<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924233</url>
  </required_header>
  <id_info>
    <org_study_id>Sym004-10</org_study_id>
    <nct_id>NCT02924233</nct_id>
  </id_info>
  <brief_title>Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer</brief_title>
  <official_title>An Open-label, Randomized, Multicenter, Phase 1b/2b Trial Investigating the Safety and Preliminary Antitumor Effects of Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symphogen A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symphogen A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2b study investigating the safety and preliminary antitumor effects of
      Sym004 in combination with nivolumab versus nivolumab monotherapy when administered every
      second week.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Symphogen made a business decision to no longer perform the clinical study
  </why_stopped>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Determination of the Dose-Limiting Toxicities (DLT) and the MTD and/or RP2D of escalating doses of Sym004 in combination with a standard dose of nivolumab</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2b: Evaluation of the antitumor effects of the RP2D of Sym004 when administered in combination with a standard dose of nivolumab as measured by Response Rate</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Sym004 + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b, dose-escalation:
Dose Level 1: Sym004 + nivolumab (Q2W)
Dose Level 2: Sym004 + nivolumab (Q2W)
Dose Level -1: Sym004 + nivolumab, if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym004 (RP2D) + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2b, dose-expansion:
Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 2b, dose-expansion:
Receiving nivolumab monotherapy (Q2W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym004</intervention_name>
    <description>Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
Sym004 will be administered at different dose-levels via infusion Q2W</description>
    <arm_group_label>Sym004 + nivolumab</arm_group_label>
    <arm_group_label>Sym004 (RP2D) + nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W</description>
    <arm_group_label>Sym004 + nivolumab</arm_group_label>
    <arm_group_label>Sym004 (RP2D) + nivolumab</arm_group_label>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Signed and dated written informed consent

          -  Male or female â‰¥18 years of age at the time of informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy &gt;3 months assessed during Screening

          -  Histologically or cytologically confirmed, locally advanced or metastatic squamous
             NSCLC

        Main Exclusion Criteria:

          -  Any antineoplastic agent (standard or investigational) within 2 weeks prior to
             starting trial treatment

          -  Radiosurgery or radiotherapy for target lesions within 2 weeks prior to starting trial
             treatment

          -  Prophylactic use of hematopoietic growth factors within 1 week prior to starting trial
             treatment

          -  Active Central Nervous System (CNS) metastases or carcinomatous meningitis

          -  Women who are pregnant

          -  Women who are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

